KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa.

Michel Michaelides, Cagri G Besirli, Yesa Yang, Thales A C DE Guimaraes, Sui Chien Wong, Rachel M Huckfeldt, Jason I Comander, José-Alain Sahel, Syed Mahmood Shah, James J L Tee, Neruban Kumaran, Anastasios Georgiadis, Pansy Minnick, Robert Zeldin, Stuart Naylor, Jialin Xu, Michael Clark, Eddy Anglade, Peggy Wong, Penny R Fleck, Albert Fung, Colleen Peluso, Angelos Kalitzeos, Michalis Georgiou, Caterina Ripamonti, Alexander J Smith, Robin R Ali, Alexandria Forbes, James Bainbridge

Am J Ophthalmol 267 122-134

PMID38871269
PMCID-
DOI10.1016/j.ajo.2024.05.034
发表日期2024-06-13
摘要

摘要

PURPOSE: To assess the safety and efficacy of AAV5-hRKp.RPGR in participants with retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa (XLRP). DESIGN: Open-label, phase 1/2 dose escalation/expansion study (ClinicalTrials.gov Identifier: NCT03252847). METHODS: Males (≥5 years old) with XLRP-RPGR were evaluated. In the dose escalation phase, subretinal AAV5-hRKp.RPGR (low: 1.0 × 1011 vg/ml; intermediate: 2.0 × 1011 vg/ml; high: 4.0 × 1011 vg/ml) was administered to the poorer-seeing eye (n = 10). Dose confirmation (intermediate dose) was carried out in 3 pediatric participants. In the dose expansion phase, 36 participants were randomized 1:1:1 to immediate (low or intermediate dose) or deferred (control) treatment. The primary outcome was safety. Secondary efficacy outcomes included static perimetry, microperimetry, vision-guided mobility, best corrected visual acuity, and contrast sensitivity. Safety and efficacy outcomes were assessed for 52 weeks for immediate treatment participants and 26 weeks for control participants. RESULTS: AAV5-hRKp.RPGR was safe and well tolerated, with no reported dose-limiting events. Most adverse events (AEs) were transient and related to the surgical procedure, resolving without intervention. Two serious AEs were reported with immediate treatment (retinal detachment, uveitis). A third serious AE (increased intraocular pressure) was reported outside the reporting period. All ocular inflammation-related AEs responded to corticosteroids. Treatment with AAV5-hRKp.RPGR resulted in improvements in retinal sensitivity and functional vision compared with the deferred group at Week 26; similar trends were observed at Week 52. CONCLUSIONS: AAV5-hRKp.RPGR demonstrated an anticipated and manageable AE profile through 52 weeks. Safety and efficacy findings support investigation in a phase 3 trial.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。